Print Page      Close Window     


SEC Filings

OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document



GnRH antagonist market takeaways 1 Large patient populations at 2.5 – 4+ million for each indication 2 Ample room for multiple market entrants 3 Patients not “one size fits all” – Availability of dosing options preferred by US Gynecologists OBE2109 potential Best in Class: 4 • Once-a-day, no adverse impact of food intake and no metabolic impact on ABT • Availability of two dosing options for both indications (ABT & No ABT) 5 Time to market: AbbVie leading and investing in early market development